UNSPSC 41131712: Erythrocytic glucose-6-phosphate dehydrogenase assay

In this classification an erythrocytic glucose-6-phosphate dehydrogenase assay is a device used to measure the activity of the enzyme glucose-6-phosphate dehydrogenase or of glucose-6-phosphate dehydrogenase isoenzymes. The results of this assay are used in the diagnosis and treatment of nonspherocytic congenital hemolytic anemia or drug-induced hemolytic anemia associated with a glucose-6-phosphate dehydrogenase deficiency.

This generic device includes assays based on fluorescence, electrophoresis, methemoglobin reduction, catalase inhibition, and ultraviolet kinetics US FDA regulates Erythrocytic glucose-6-phosphate dehydrogenase assay under 21 CFR 864.736 and under FDA product code JBI.

UNSPSC 41131712 Erythrocytic glucose-6-phosphate dehydrogenase assay, a Commodity code, does not align with the recent state and local procurement activity currently tagged under it. The source shows nine recent opportunities, but only one—the Pinellas County drug standards procurement—involves laboratory testing materials with any relevance to diagnostic assay work; the rest cover offender drug testing services, occupational medical screening, urinalysis services, blood draw kits, and naloxone procurement. The mismatch suggests this code may be incorrectly applied to broader drug-testing and forensic-chemistry procurements rather than to the specific enzymatic deficiency diagnostic test it nominally describes. State and local governments are actively buying drug-testing services, laboratory supplies for forensic and clinical use, and occupational health screening, but not glucose-6-phosphate dehydrogenase assays specifically.

Recent activity spans Texas (Collin County offender testing and health-care lab services, Texas Comptroller statewide chemical laboratory equipment), Georgia (Gwinnett County drug testing supplies), North Carolina (City of Charlotte drug and alcohol testing), New Mexico (Bernalillo County occupational medical health), Oregon (Benton County urinalysis for family treatment court, State of Oregon clozapine assay), Florida (Seminole County naloxone and Pinellas County drug standards), and Wisconsin (University of Wisconsin blood draw kits). The issuing bodies include county criminal-justice and health departments, state purchasing divisions, cities, universities, and specialized courts. Collin County appears twice—once for offender testing (RFP 2026-327, due July 23, 2026, $600,000 estimated value) and once for clinical laboratory services (IFB 2025-166, due October 2, 2025, $70,000 estimated annual value). The Pinellas County drug standards procurement (ITQ 26-0305-ITQ, due April 23, 2026) specifies 131 line items of certified reference materials for forensic analysis, funded through the Paul Coverdell Forensic Sciences Improvement Act Program with $49,034.00 designated for equipment and supplies. The code shows no material procurement activity in its stated scope.